insights_auto
Zašto je 688235 skočio 4,06%?
Istražite detaljnijechevron_right
688235:SHA
BeOne Medicines AG
255,98 CNY
arrow_upward
+4,06%(+9,99) 1D
16. lis, 15:00:00 GMT+8 · CNY
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za 688235...
Otvori
253,20 CNY
Najviša
268,18 CNY
Najniža
252,09 CNY
Trž. kap.
303,26 mlr.
Prosj. kol.
2,81 mil.
Količina
5,69 mil.
P/E omjer
91,43
52-tjed. najviša
319,24 CNY
52-tjed. najniža
205,51 CNY
EPS
2,80 CNY
Broj djelatnika
12 tis.
Otvori
253,20 CNY
Najviša
268,18 CNY
Najniža
252,09 CNY
Trž. kap.
303,26 mlr.
Prosj. kol.
2,81 mil.
Količina
5,69 mil.
P/E omjer
91,43
52-tjed. najviša
319,24 CNY
52-tjed. najniža
205,51 CNY
EPS
2,80 CNY
Broj djelatnika
12 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
ad-hoc-news.de
·
prije 21 sat
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
BeOne Medicines AG – informacije
Glavni izvršni direktorJohn Vincent Oyler | John Vincent Oyler
Zaposlenici12 tis.
Osnovano28. lis 2010.
Sjedište-
Sektor-
Web-lokacijabeonemedicines.com